Kesler Norman & Wride LLC Has $7.80 Million Holdings in Cencora, Inc. (NYSE:COR)

Kesler Norman & Wride LLC cut its stake in Cencora, Inc. (NYSE:COR) by 7.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 34,727 shares of the company’s stock after selling 2,638 shares during the period. Cencora accounts for 1.7% of Kesler Norman & Wride LLC’s portfolio, making the stock its 10th biggest position. Kesler Norman & Wride LLC’s holdings in Cencora were worth $7,803,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. United Bank boosted its stake in shares of Cencora by 4.2% in the 3rd quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after purchasing an additional 225 shares during the last quarter. Public Sector Pension Investment Board boosted its position in Cencora by 53.2% during the third quarter. Public Sector Pension Investment Board now owns 6,908 shares of the company’s stock valued at $1,555,000 after acquiring an additional 2,400 shares during the last quarter. Arete Wealth Advisors LLC boosted its position in Cencora by 4.9% during the third quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company’s stock valued at $541,000 after acquiring an additional 113 shares during the last quarter. Benjamin Edwards Inc. raised its position in shares of Cencora by 1,552.8% in the 3rd quarter. Benjamin Edwards Inc. now owns 9,041 shares of the company’s stock worth $2,035,000 after acquiring an additional 8,494 shares in the last quarter. Finally, Ascent Group LLC raised its position in shares of Cencora by 245.4% in the 3rd quarter. Ascent Group LLC now owns 6,833 shares of the company’s stock worth $1,538,000 after acquiring an additional 4,855 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Finally, Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Price Performance

Shares of NYSE COR opened at $277.44 on Wednesday. The stock has a market cap of $53.80 billion, a price-to-earnings ratio of 39.46, a PEG ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $280.70. The firm’s 50-day simple moving average is $255.18 and its 200 day simple moving average is $241.79.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is 31.29%.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock worth $8,034,778 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.